A

AIM ImmunoTech

D
AIM
USD
0.0064
(2.6122%)
Market Closed
400.00
Volume
-0.325
EPS
-
Div Yield
-0.441053
P/E
14,364,161.35
Market Cap
Today
2.6122%
1 Week
1.781%
1 Month
-6.889%
6 Months
-40.917%
12 Months
-45.935%
Year To Date
-43.506%
All Time
0%

Title:
AIM ImmunoTech

Sector:
Healthcare
Industry:
Biotechnology
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
Do you need help or have a question?